600056 China Meheco Group
- 10.53
- +0.07+0.67%
China Meheco Group News
China Meheco Group (600056.SH): Notice of approval for the listing application of chemical raw material active pharmaceutical ingredient of Dapoxetine hydrochloride.
China Meheco Group (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., has received the Approval Notice of Listing Application for Chemical Raw Materials of Dapoxetine Hydrochloride issued by the State Administration of Drug Administration. This pharmaceutical ingredient is used to treat premature ejaculation (PE) in male patients aged 18 to 64.
China Meheco Unit's Cefuroxime Sodium Injection Passes Drug Regulator's Evaluation
China Meheco Group (600056.SH): Injection Cefuroxime Sodium Obtains Drug Supplement Application Approval Notice.
China Meheco Group (600056.SH) announced that its wholly-owned subsidiary Hainan General Sanyo Pharmaceutical Co., Ltd. has received five issued approval notices for supplemental applications for injection use of cefuroxime sodium from the National Medical Products Administration. The drug has passed the consistency evaluation of quality and efficacy for generic drugs. Cefuroxime sodium for injection was originally developed by Glaxo in the United Kingdom and is a second-generation cephalosporin antibiotic with broad-spectrum antibacterial activity. It is suitable for a wide range of infections caused by specific susceptible strains of microorganisms, including respiratory tract infections, otolaryngology infections, urinary tract infections, skin and soft tissue infections.
China Meheco Group (SHSE:600056) Takes On Some Risk With Its Use Of Debt
LBX Pharmacy Chain Joint Stock (603883.SH): The 18 provinces it has covered account for 3/4 of the China Meheco Group's retail market share.
LBX Pharmacy Chain Joint Stock (603883.SH) stated in the institutional investor communication activity that it is one of the enterprises with the widest coverage of pharmaceutical retailing in China, with broad coverage providing the company with broad development space and great potential for improving market share. By the end of 2023, the company's chain network (excluding alliances) will cover 18 provincial markets and more than 150 cities at or above the prefecture level, with a total of 13,574 stores nationwide. The 18 provinces already covered by the company account for 3/4 of the pharmaceutical retail market in China. The company plans to focus on advantageous provincial markets and actively expand the sinking market. The company is focused.
Beijing Strong Biotechnologies, Inc. (stock code 300406.SZ): China MEHECO Group plans to increase shareholding by no less than 30 million yuan.
On June 25th, Gelunhui reported that Beijing Strong Biotechnologies, Inc. (300406.SZ) disclosed that China Meheco Group, a shareholder holding more than 5% of the shares (referred to as the "shareholding entity"), plans to increase the company's stocks through legal means such as centralized competitive trading and bulk trading from June 25th, 2024 to December 24th, 2024. The planned increase in the company's shareholding amount is no less than 30 million yuan (including the part already increased as of June 25th, 2024), and the required funds for the increase are self-owned.
Just Three Days Till China Meheco Group Co., Ltd. (SHSE:600056) Will Be Trading Ex-Dividend
Individual Investors Own 42% of China Meheco Group Co., Ltd. (SHSE:600056) Shares but Private Companies Control 53% of the Company
China Meheco Group (stock code: 600056.SH) will distribute a dividend of 0.21019 yuan per share for the year 2023. The record date is June 26th.
China Meheco Group (600056.SH) announced that it will implement the annual equity distribution in 2023, distributing a cash dividend of 0.21019 yuan (including tax) per share with the registration date on June 26th.
China Approves Meheco Unit's Supplementary Drug Application for Ear Disorder Medication
UBS Group: State-owned enterprise reform may promote the re-evaluation of the valuation of pharmaceutical stocks, with Sinopharm as the preferred choice.
UBS Group released a research report stating that it gave a buy rating to Sinopharm (01099) with a target price raised from HKD 27.3 to HKD 28.6. The target price of Sh Pharma (02607) is maintained at HKD 14.9, and the rating is also "buy". The current stock price of China Meheco Group has a predicted PE ratio of 8.2 in 2025, but the compound annual growth rate of earnings per share from 2024 to 2026 is predicted to be 11.1%, corresponding to the predicted PE ratio of 15.3 and the 6.6% compound annual growth rate of earnings per share of its US counterparts. The bank believes that the market has not taken into account the industry leader in the Chinese market.
China Pharmaceutical (600056.SH): Elects Yang Guang as Chairman of the Company
China Pharmaceutical (600056.SH) announced that the company will hold its second meeting in 2024 on May 30, 2024...
[Broker Focus] CMB International maintains a demand recovery in China's pharmaceutical industry in the second half of the year, and there is a high degree of certainty that overseas C (D) MO companies' performance will recover
Jinwu Financial News | CMB International said it will maintain the consensus on the recovery of demand in China's pharmaceutical industry in the second half of 24. After experiencing a sharp increase in R&D demand due to the COVID-19 pandemic and two years of sluggish financing in the global biomedical industry, order growth from overseas companies began to deteriorate in 2023, and 1Q24 did not show an improvement trend. The growth rate of new orders from many companies slowed down or grew negatively. Despite pressure from new orders, management at a number of overseas companies is still expecting to see a recovery in industry demand and company performance in the second half of '24, including upstream life sciences companies and pre-clinical CRO company management
[Broker Focus] CMB International: China's pharmaceutical industry is expected to return to healthy growth and continues to be optimistic about leading innovative drugs and devices and high-growth medical consumer stocks
Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has declined by 21.4%, significantly outperforming the MSCI China Index by 32.5%. The MSCI China Healthcare Index has only rebounded 9% since its low on April 19; currently, the dynamic price-earnings ratio of the industry index is 26.3 times, which is still below the 12-year historical average. It is expected that the medical equipment trade-in policy will soon be implemented. The policy is strong, wide-ranging, and has a long duration, which will effectively stimulate demand for medical devices. The bank looks forward to the introduction of a national policy to support innovative drugs and innovative devices. The bank expects that as industry-supporting policies fall one after another
China Meheco Group (SHSE:600056) Investors Are Sitting on a Loss of 20% If They Invested a Year Ago
[BT Financial Report Momentary Analysis] China Pharmaceutical 2023 Report: Steady Growth, High Quality Development Continues to Advance
China Pharmaceutical (stock code: 600056), as a well-known domestic enterprise in the entire healthcare industry chain, recently released its 2023 financial report. Through in-depth analysis of this financial report, we can observe that the company has maintained a steady development trend in a complex and changing market environment, and all financial data have shown a positive growth trend. First, judging from balance and liability data, the total assets of China Pharmaceuticals at the end of the reporting period reached 37.409 billion yuan, an increase of 4.21% compared with 35.899 billion yuan at the beginning of the period. This growth was mainly due to the steady expansion of the company's business and effective asset management.
China Meheco Group Chairman, Vice Chairman Resign
China Pharmaceutical (600056.SH): Chairman and Director Li Yadong Resigns
Gelonghui, May 14, 丨 China Pharmaceutical (600056.SH) announced that the board of directors of the company received written resignation reports from Mr. Li Yadong and Mr. Wang Xiao respectively. Due to job adjustments, Mr. Li Yadong applied to resign from relevant positions as the chairman (legal representative), director and special committee of the board of directors of the company. Due to job adjustments, Mr. Wang Xiao applied to resign as vice chairman and director of the company. As of the disclosure date of this announcement, Mr. Li Yadong and Mr. Wang Xiao did not hold shares in the company.
We Think You Should Be Aware Of Some Concerning Factors In China Meheco Group's (SHSE:600056) Earnings
China Meheco Group Co., Ltd.'s (SHSE:600056) Business Is Yet to Catch Up With Its Share Price
Analysis
Price Target
No Data
